阳光诺和：子公司拟200万元将孙公司70%股权转让给中健培联

Core Insights - Sunshine Nuohe announced the signing of a share transfer agreement between its wholly-owned subsidiary Beijing Nuohe Demai Pharmaceutical Technology Co., Ltd. and Beijing Zhongjian Peilian Medical Research Institute, resulting in the transfer of 70% of Shanghai Meisuke Medical Data Co., Ltd. to Zhongjian Peilian for a cash consideration of 2 million yuan [1] - The transaction aims to address the long-term losses of Meisuke Medical Data, enhance asset operation efficiency, reduce management costs, and improve the sustainability of operations [1] Summary by Sections - Transaction Details - Nuohe Demai will transfer 70% of its stake in Meisuke Medical Data for 2 million yuan [1] - Nuohe Meichuang will transfer its 30% stake in Meisuke Medical Data for 0 yuan [1] - Post-transaction, Nuohe Demai will no longer hold any equity in Meisuke Medical Data, which will be excluded from the consolidated financial statements [1] - Rationale for the Transaction - Meisuke Medical Data has been in a state of long-term losses [1] - The decision is based on a comprehensive assessment of the company's actual situation [1] - The goal is to enhance asset operation efficiency, lower management costs, and strengthen the company's ongoing operational capabilities [1]